Cellegy Pharmaceuticals Inc.

News & Analysis

cellegy pharmaceuticals inc. - All News and Analysis

• Business news in brief

  - 2006-04-12

  IN THE REGION Rohm & Haas expects 29% leap in quarterly profit Rohm & Haas Co. said yesterday that first-quarter per-share earnings were likely to be 29 percent higher than year-ago earnings. Higher profit was coming in while oil prices were soaring, which typically has added costs to...

  Tags: Associated Press, Cellegy Pharmaceuticals Inc., earnings, FINANCE, Google Inc., Government, Philadelphia, SALES, U.S. Bancorp Piper Jaffray Inc., US Airways Group Inc., Volkswagen AG

• Stocks on the Rise.

  - 2005-04-19

  M2 PRESSWIRE-19 April 2005-WallStreetGrapevine: Stocks on the RiseC1994-2005 M2 COMMUNICATIONS LTD RDATE:19042005 Wall Street, NYC - Today wallstreetgrapevine.com announced; Bio-Matrix Scientific Group Inc.(BMXG.PK), Stemcells Inc.(Nasdaq SC: STEM), Infinex Ventures Inc. (IFNX.OB), and Cellegy Pharmaceuticals Inc. (Nasdaq NM: CLGY); as their...

  Tags: Cellegy Pharmaceuticals Inc., FDA, Government, Nasdaq Stock Market Inc., stem-cell, StemCells Inc., stock

• Oppositions filed to Cellegy hemorrhoid treatment patent in Europe.(Brief Article)

  - 2001-06-01

  Cellegy Pharmaceuticals, Inc. (S. San Francisco, CA; 650-616-2200) announced that its European attorneys have advised the company that two oppositions have been filed with the European Patent Office regarding Cellegy's European Patent 0719145B1. This patent is directed to the manufacture and use of nitroglycerin...

  Tags: Cellegy Pharmaceuticals Inc., European Patent Office, patent

• Cellegy Pharmaceuticals granted anogesic patent in Europe.(Brief Article)

  - 2000-09-01

  Cellegy Pharmaceuticals, Inc. (S. San Francisco, CA; 650-616-2200) announced that the European Patent Office has granted Cellegy Patent Number 0719145B1 covering the manufacture and use of nitroglycerin ointment and related compounds for the treatment of anal disorders, including anal fissures and various hemorrhoidal conditions. The...

  Tags: Cellegy Pharmaceuticals Inc., European Patent Office, marketing, patent, U.S.

• Cellegy Pharmaceuticals Inc. CEO K. Michael Forrest talks to The Wall Street Transcript

  - 1999-03-15

  NEW YORK--BUSINESS WIRE--March 15, 1999--The Wall Street Transcript has published an in-depth interview with K. Michael Forrest of Cellegy Pharmaceuticals, Inc. (Nasdaq:CLGY), in which he talks at length about his company's future. He says, "Cellegy today is a company that has evolved from a focus on pure dermatology research...

  Tags: Business Wire, Cellegy Pharmaceuticals Inc., FINANCE, inflammation, investor, Strategy